Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
April 08, 2024 16:30 ET
|
Cellectis Inc.
Cellectis announces that preliminary data exploring novel TALEN® editing process in HSPCs will be presented at ASGCT 2024
Monthly information on share capital and company voting rights
April 04, 2024 16:30 ET
|
Cellectis Inc.
PARIS, April 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
April 02, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of MAA by the EMA for obe-cel for patients with B-ALL
Autolus Therapeutics Announces Changes to its Board of Directors
April 01, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Announces Changes to its Board of Directors
Global CAR-T Cell Therapy Market Expected to Surge to USD 34.04 Billion by 2034 with a CAGR of 23.33%
March 27, 2024 08:50 ET
|
Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global...
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics today provided a business update and reported financial results for the quarter and year ending December 31, 2023.
CAR-T Funding Report 2024: Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions
March 18, 2024 04:52 ET
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2024" report has been added to ...
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
March 14, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
March 12, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
Autolus Therapeutics announces publication in Blood Cancer Journal
March 11, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces publication in Blood Cancer Journal